Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOA | P21397 | 2/20 | 0.60 |
| ▸ | MAOB | P27338 | 2/20 | 0.60 |
| ▸ | KCNJ1 | P48048 | 1/20 | 0.47 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.47 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.47 |
| ▸ | CTSS | P25774 | 2/20 | 0.44 |
| ▸ | CTSK | P43235 | 2/20 | 0.44 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.43 |
| ▸ | LOXL2 | Q9Y4K0 | 2/20 | 0.42 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | EPHX1 | P07099 | 2/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | CTSL | P07711 | 1/20 | 0.40 |
| ▸ | CTSB | P07858 | 1/20 | 0.40 |
| ▸ | CTSC | P53634 | 1/20 | 0.40 |
| ▸ | DAO | P14920 | 1/20 | 0.39 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10479940 | 0.97 | MAOA (0.57) | MAOAMAOBKCNJ1KCNH2HRH3 | |
| SCHEMBL10479942 | 0.97 | MAOA (0.57) | MAOAMAOBKCNJ1KCNH2HRH3 | |
| SCHEMBL23588057 | 0.91 | MAOB (0.65) | MAOAMAOBKCNJ1KCNH2HRH3 | |
| SCHEMBL11249312 | 0.90 | MAOA (0.50) | MAOAMAOBKCNJ1KCNH2HRH3 | |
| SCHEMBL8456405 | 0.88 | MAOA (0.49) | MAOAMAOBKCNJ1KCNH2HRH3 | |
| SCHEMBL24358834 | 0.88 | MAOB (0.55) | MAOAMAOBKCNJ1KCNH2HRH3 | |
| SCHEMBL24358781 | 0.88 | MAOB (0.55) | MAOAMAOBKCNJ1KCNH2HRH3 | |
| SCHEMBL12807811 | 0.84 | HRH3 (0.59) | MAOAMAOBKCNJ1KCNH2HRH3 | |
| SCHEMBL9186117 | 0.84 | MAOB (0.58) | MAOAMAOBKCNJ1KCNH2HRH3 | |
| SCHEMBL10341709 | 0.83 | MAOB (0.57) | MAOAMAOBKCNJ1KCNH2HRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3802730-B1 | LIQUID-CRYSTAL MEDIUM | MERCK PATENT GMBH (DE) | 2023-04-19 | — | — | EP | disclosed |
| US-20220119711-A1 | LIQUID-CRYSTAL MEDIUM | MERCK PATENT GMBH (DE) | 2022-04-21 | — | — | US | disclosed |
| EP-3529332-B1 | LIQUID-CRYSTAL MEDIUM | MERCK PATENT GMBH (DE) | 2020-11-25 | — | — | EP | disclosed |
| US-9617473-B2 | Switch element comprising a liquid-crystalline medium | MERCK PATENT GMBH (DE) | 2017-04-11 | — | — | US | disclosed |
| US-8680091-B2 | 6-arylalkylamino-2,3,4,5-tetrahydro-1H-benzo[d]azepines as 5-HT2C receptor agonists | ELI LILLY AND COMPANY (US) | 2014-03-25 | — | — | US | disclosed |
| US-20110269745-A1 | 6-ARYLALKYLAMINO-2,3,4,5-TETRAHYDRO-1H-BENZO[d]AZEPINES AS 5-HT2C RECEPTOR AGONISTS | ELI LILLY AND COMPANY (US) | 2011-11-03 | — | — | US | disclosed |
| US-5876626-A | HIGH SPEED SWITCHING | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 1999-03-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110269745-A1 | 6-ARYLALKYLAMINO-2,3,4,5-TETRAHYDRO-1H-BENZO[d]AZEPINES AS 5-HT2C RECEPTOR AGONISTS | HTR2C, HTR1A, HTR2A | MAOA 327/4885MAOB 380/4885KCNJ1 1893/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.